Regenerative Endodontics: Stem Cells, Scaffolds, and Clinical Protocols

The field of endodontics has undergone a paradigm shift over the past two decades. Traditional root canal therapy, while effective at eliminating infection and preserving teeth, ultimately results in a non-vital tooth that is more brittle and susceptible to fracture. Regenerative endodontics offers an entirely different vision: the biological replacement of damaged pulp-dentin complex with functional, living tissue. This article explores the biological foundations, technological advances, and clinical protocols that define modern regenerative endodontic procedures.

The Biological Basis of Pulp Regeneration

Regenerative endodontics rests on the principles of tissue engineering: the triad of stem cells, scaffolds, and growth factors. In the pulpal context, these elements converge to create an environment conducive to tissue formation within the root canal space.

Stem Cell Sources in Dentistry

Dental tissues harbor several distinct populations of mesenchymal stem cells (MSCs) with remarkable regenerative potential. Dental pulp stem cells (DPSCs) were first isolated by Gronthos and colleagues in 2000 from extracted third molars and demonstrated the capacity to form dentin-pulp-like complexes when transplanted into immunocompromised mice. Since that landmark discovery, additional dental stem cell populations have been identified: stem cells from human exfoliated deciduous teeth (SHED), periodontal ligament stem cells (PDLSCs), dental follicle progenitor cells (DFPCs), and stem cells from the apical papilla (SCAP).

SCAP are particularly relevant to regenerative endodontic procedures in immature teeth. Located at the apex of developing roots, these cells survive even after pulp necrosis because of their proximity to the periapical blood supply. They are thought to be the primary cell source responsible for continued root development observed after successful revascularization procedures. SCAP exhibit higher proliferation rates and telomerase activity compared to DPSCs, making them ideally suited for the regenerative environment.

Growth Factors and Signaling Molecules

The induction of a blood clot into the canal space during regenerative procedures delivers a rich cocktail of growth factors from platelets and the periapical tissue. Platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMPs), and insulin-like growth factor (IGF) are all present in physiologically relevant concentrations within the induced clot. These molecules orchestrate cell migration, proliferation, and differentiation through complex signaling cascades.

Dentin itself serves as a reservoir of bioactive molecules. During development, odontoblasts sequester growth factors within the dentin matrix. Application of EDTA during regenerative procedures demineralizes dentin and releases these embedded factors, including TGF-β1, BMP-2, and VEGF, which further stimulate stem cell differentiation and angiogenesis. This concept of dentin as a "bioactive matrix" is central to the success of regenerative protocols.

Scaffold Materials and Design Considerations

The scaffold provides a three-dimensional framework for cell attachment, proliferation, and organized tissue formation. The ideal scaffold for regenerative endodontics should be biocompatible, biodegradable, and capable of supporting angiogenesis while providing mechanical stability during tissue maturation.

Blood clot scaffolds, generated by intentional over-instrumentation into periapical tissue, represent the most clinically accessible option and form the foundation of the American Association of Endodontists (AAE) regenerative protocol. Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) offer more concentrated growth factor delivery with improved handling properties. PRF, in particular, has gained popularity due to its simplified preparation protocol that requires no anticoagulants or exogenous thrombin.

Synthetic and natural polymer scaffolds under investigation include collagen, hyaluronic acid, chitosan, polylactic-co-glycolic acid (PLGA), and silk fibroin. Hydrogel systems allow injectable delivery and can be engineered to release growth factors in a controlled, spatiotemporal manner. Decellularized dental pulp extracellular matrix has emerged as a promising biomimetic scaffold that recapitulates the native tissue microenvironment with preserved biochemical cues.

Clinical Protocols: Revascularization and Beyond

Patient Selection Criteria

Current regenerative endodontic protocols are primarily indicated for immature permanent teeth with necrotic pulps and open apices. The AAE clinical considerations document specifies several criteria: a tooth with an open apex (typically >1.0 mm apical diameter), pulp necrosis with or without apical periodontitis, adequate remaining tooth structure for restoration, and patient compliance with follow-up appointments. Both traumatic injuries and developmental anomalies such as dens evaginatus are common etiologies in this population, which is predominantly pediatric and adolescent.

Contraindications include teeth with vertical root fractures, severe crown destruction precluding isolation, allergy to medicaments used in the protocol, and patients with conditions that impair healing such as uncontrolled diabetes or immunosuppression. The presence of a sinus tract or periapical radiolucency is not a contraindication; indeed, resolution of these findings is one of the primary outcome measures.

The AAE Regenerative Protocol

The AAE protocol proceeds in two appointments. At the first visit, after achieving local anesthesia without vasoconstrictor (to avoid compromising the blood supply to stem cells in the apical papilla), the tooth is isolated with a rubber dam and accessed. The canal is gently irrigated with 1.5% sodium hypochlorite (NaOCl) using a side-vented needle positioned 2 mm short of the working length to minimize cytotoxicity to periapical tissues. Irrigation volume is approximately 20 mL per canal over 5 minutes, followed by irrigation with 17% EDTA to neutralize the NaOCl and release growth factors from dentin.

The canal is dried with paper points and a triple antibiotic paste (TAP) consisting of ciprofloxacin, metronidazole, and minocycline at a 1:1:1 ratio is delivered below the cementoenamel junction (CEJ) using a Lentulo spiral or syringe. Alternatively, calcium hydroxide may be used as an intracanal medicament, though some studies suggest TAP may provide superior disinfection. The tooth is temporized with a double seal of Cavit and glass ionomer.

At the second appointment 2 to 4 weeks later, after confirming resolution of clinical signs and symptoms, the tooth is re-isolated and anesthetized with 3% mepivacaine without vasoconstrictor. The intracanal medicament is removed with copious irrigation using 17% EDTA. The canal is dried, and a size #20 or #25 K-file is deliberately passed 2 mm beyond the apex to induce bleeding into the canal space. The blood clot is allowed to form to approximately 3 mm below the CEJ.

A resorbable collagen matrix (such as CollaPlug) is placed over the clot to serve as an internal matrix, followed by white MTA or Biodentine placed directly over the matrix to create a 3 mm coronal seal. The tooth is then restored with composite or a full-coverage restoration as indicated. Follow-up at 3, 6, 12, and 24 months with periapical radiographs and clinical examination monitors for resolution of apical periodontitis, continued root development, and positive response to pulp sensibility testing.

Treatment Outcomes and Success Rates

Systematic reviews report survival rates of regenerative endodontic procedures ranging from 90% to 100%, with success rates (defined as resolution of apical periodontitis) of approximately 80% to 95%. The primary desired outcome—continued root development—is achieved in 50% to 80% of cases, with increases in root length, root wall thickness, and apical closure documented radiographically.

Several factors influence outcomes. Patient age under 18 years, larger preoperative apical diameter, and shorter duration of infection are associated with more favorable results. The type of intracanal medicament appears significant: calcium hydroxide has been associated with greater increases in root length compared to TAP, though TAP may provide better disinfection. Concentration of TAP is critical—paste at 1 mg/mL or lower minimizes stem cell cytotoxicity while maintaining antimicrobial efficacy. The choice of coronal barrier also matters: Biodentine has been proposed as an alternative to MTA due to reduced discoloration potential, an important consideration in anterior teeth.

Histological Outcomes: Repair Versus Regeneration

Histological examination of teeth treated with regenerative protocols reveals that true regeneration of the pulp-dentin complex—with odontoblast-like cells lining the dentin wall, organized connective tissue, and neurovascular elements—is achieved in only a minority of cases. More commonly, the tissue formed is reparative in nature, consisting of cementum-like tissue, bone-like tissue, and fibrous connective tissue rather than true dental pulp.

This distinction between repair and regeneration has prompted research into strategies that more precisely recapitulate developmental signaling pathways. Delivery of exogenous growth factors, gene therapy approaches to upregulate BMP and VEGF expression, and cell-homing strategies using chemokine gradients represent active areas of investigation. The ultimate goal remains the predictable regeneration of a functional, innervated pulp-dentin complex rather than nonspecific tissue repair.

Emerging Technologies and Future Directions

Cell-Based Approaches

While current clinical protocols rely on cell-homing mechanisms (inducing the migration of host stem cells into the canal space), cell-based therapies involving the transplantation of ex vivo expanded autologous or allogeneic stem cells represent the next frontier. Pilot clinical trials in Japan have demonstrated the feasibility of transplanting autologous DPSCs with G-CSF-mobilized peripheral blood into pulpectomized teeth, with some evidence of pulp-like tissue regeneration on histological analysis.

Allogeneic cell sources would offer "off-the-shelf" availability but face immunological challenges. Mesenchymal stem cells are generally considered immunoprivileged due to low MHC class I expression and absence of MHC class II and co-stimulatory molecules. However, long-term safety data regarding tumorigenicity, ectopic tissue formation, and immune sensitization remains limited, and regulatory pathways for cell-based dental products are still evolving.

Bioprinting and Organ-on-a-Chip

Three-dimensional bioprinting enables precise spatial deposition of cells, scaffolds, and bioactive factors to fabricate tissue constructs with anatomically relevant architecture. Dental pulp organoids have been developed that recapitulate key features of native pulp tissue, including odontoblast polarization and tubular dentin formation. Organ-on-a-chip platforms incorporate microfluidic channels to simulate vascular perfusion and enable real-time monitoring of tissue responses to biomaterials and therapeutic agents.

Gene Therapy and Molecular Approaches

Viral and non-viral vectors can deliver genes encoding BMPs, VEGF, and other morphogens directly to the canal space, achieving sustained local expression without the limitations of recombinant protein delivery (short half-life, supraphysiological dosing). Ultrasound-mediated gene delivery (sonoporation) and nanoparticle-based systems offer less immunogenic alternatives to viral vectors. CRISPR-Cas9 gene editing technologies open the possibility of activating endogenous developmental programs in resident stem cells to direct lineage-specific differentiation.

Challenges and Clinical Translation

Several barriers impede widespread clinical adoption of advanced regenerative endodontic therapies. Standardization of cell processing protocols under Good Manufacturing Practice (GMP) conditions is costly and technically demanding. Regulatory frameworks for cell-based products vary significantly across jurisdictions, with the United States FDA classifying such products under the human cells, tissues, and cellular and tissue-based products (HCT/P) regulations. Reimbursement pathways are unclear, and the cost-benefit ratio compared to conventional root canal therapy or extraction with implant placement has not been rigorously evaluated.

Long-term outcomes beyond 5 years remain sparsely reported, and the risk of late complications—including pulp canal obliteration, internal resorption, and coronal discoloration—requires ongoing surveillance. Standardization of outcome measures across studies is needed; the lack of consensus on what constitutes "success" in regenerative endodontics complicates meta-analysis and evidence synthesis.

Conclusion

Regenerative endodontics has progressed from experimental concept to established clinical protocol for immature necrotic teeth. The AAE regenerative procedure, while technically straightforward, represents only the first generation of biologically based endodontic treatments. As our understanding of dental stem cell biology, biomaterial science, and developmental signaling pathways continues to deepen, the prospect of predictable, complete regeneration of the pulp-dentin complex moves closer to clinical reality. The transition from repair to true regeneration will require continued investment in basic science, translational research, and rigorous clinical trials that establish safety, efficacy, and long-term durability.